Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. - Wikidata - wikimedia - TriplyDB

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

http://www.wikidata.org/entity/Q48736327

about

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management.Inhaled corticosteroids plus long-acting beta2-agonists as a combined therapy in asthma.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.Safe use of long-acting β-agonists: what have we learnt?Long-acting beta(2)-agonist and inhaled corticosteroid combination therapy for adult persistent asthma: systematic review of clinical outcomes and economic evaluation.Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis.Using case management to increase antiinflammatory medication use among a managed care population with asthma.Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control.Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.Assessment of lung deposition and analysis of the effect of fluticasone/salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (pMDI) in stable persistent asthma patients using functional respiratory imaging.Use and safety of long-acting β2-agonists for pediatric asthma

P2860

Q24199079-95D1C771-CFF2-4F7B-8F0E-584873B50A50 Q24235303-4D9E9B79-1011-47F6-8241-656E1BCC39B6 Q24235964-183EBD14-026C-421A-8767-6B5D36825720 Q24240464-692190B4-7C13-423B-86D2-CAE861999EC3 Q24241740-26CEB482-49A3-49AC-BB57-FD73C69F9096 Q24245719-DFD98B54-19AC-4DF2-8A52-45071E147A32 Q24794527-E5C36B06-593E-4EC7-8E5E-A235AEBCD15C Q33922403-F86237C5-DE62-4603-9CDE-DB929379ECE2 Q34523871-E730CE32-7D8E-4020-AB0F-79E9C331CB44 Q35040750-DF8C943A-5F30-4489-9D71-1DA83659F37B Q35627925-0435FDD1-F2B6-45E9-A4EE-ECC2C02FAEB7 Q36246222-BFFF76F8-9788-4512-83AC-103455630855 Q37869146-82972844-5840-44A5-AEC2-C03E50D95750 Q38043452-863D6327-2843-4100-B18B-01F19AE83731 Q38219526-1E55FDC9-097F-4881-AB58-7835449721F1 Q39409694-70F1C896-D449-49D9-BA45-19F2C47A72AC Q44229943-A340FE9C-83DA-4D8C-8671-0E549A1AE5D6 Q50697600-7C15049C-A02B-4B7D-ABDD-F1C7AD27C484 Q51139530-BFCF0F61-884B-4E77-AE16-C08F170913EF Q51316768-9BA5A19C-FF8A-4674-93F5-6C971E9ED192 Q57821604-BB6E1E22-CCC5-4F46-B750-678C346B31DC

P2860

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

http://www.wikidata.org/entity/Q48736327

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@en

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@nl

type

label

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@en

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@nl

prefLabel

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@en

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@nl

P1433

Q48736327-44F8300B-A5D2-4AD8-844A-7E30F561AF56

P1476

Q48736327-27C12E3E-519C-4A79-BD38-0C7F43F8A111

P2093

Q48736327-16E0D6DC-FE82-48C9-B4F9-E6F007E02476

Q48736327-17BC72A7-E26F-422D-83F6-035CA180D155

Q48736327-3CDD181E-E0A0-47F4-AC0B-010B2C69681C

Q48736327-456BA48C-D806-470D-99FC-5D86262CC7B6

Q48736327-80751A3E-B275-4206-A337-7EBA58857959

Q48736327-CD72924D-BD5F-48B6-BFCC-3C3129379D04

Q48736327-E90777EF-F47D-44EE-B555-851A88CCA96D

P2860

Q48736327-010C6C33-443B-4AE0-A845-CA4C910A7099

Q48736327-0E8C347C-3CD7-4BD4-8B02-E283E95CCC5E

Q48736327-64C8FCA1-084D-4E00-A82E-B465426EA69D

Q48736327-72B9A3FD-56F3-4A9C-A778-803A62AE2512

Q48736327-CD93A047-8E98-489F-BC24-B6B45D709E16

Q48736327-DCC71ED5-1850-4DAB-87DC-DB06EF746D17

Q48736327-FFA14275-43D0-4795-8A49-284CFF15936E

P304

Q48736327-788AB0EB-D7F2-43EA-9AAE-0C70701A0C3F

P31

Q48736327-14F55711-0659-4800-9FE5-D6E75781E69C

P356

Q48736327-52F564C6-867A-4E16-9892-4A8640DF6F78

P407

Q48736327-C6541C8C-9D82-4BD0-AE97-959B81572181

P433

Q48736327-970F0973-EC1C-4A03-AD10-B4B9AE1B8249

P478

Q48736327-F07DA4B8-0204-445D-9317-91C4090F6B3B

P577

Q48736327-7EA69F9F-128E-421D-B2A4-41017B47D582

P698

Q48736327-53CD85E8-A3EF-40DB-A069-58233C9F1917

P356

02770909909055422

P1433

Journal of Asthma

P1476

Salmeterol added to inhaled co ...... : a randomized clinical trial.

@en

P2093

Anderson WH

http://www.w3.org/2001/XMLSchema#string

Church NL

http://www.w3.org/2001/XMLSchema#string

Emmett AH

http://www.w3.org/2001/XMLSchema#string

Gillman SA

http://www.w3.org/2001/XMLSchema#string

Kelsen SG

http://www.w3.org/2001/XMLSchema#string

Lanier BQ

http://www.w3.org/2001/XMLSchema#string

Rickard KA

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung

Use of inhaled corticosteroids in patients with mild asthma.

Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.

Molecular mechanisms of steroid action in asthma.

Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.

Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways.

P304

703-715

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/02770909909055422

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10609625

http://www.w3.org/2001/XMLSchema#string